PLUS1
9.60
0.33 (3.56%)
0.33 (3.56%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 14,862 |
|
|||||
| News | - | ||||||
| Day High | 9.79 | Low High |
|||||
| Day Low | 8.80 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Pharvaris NV | PHVS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.33 | 3.56% | 9.60 | 19:52:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 9.79 | 8.80 | 9.79 | 9.60 | 9.27 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 328 | 14,862 | $ 9.50 | $ 141,220 | - | 1.77 - 27.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:33:27 | 1 | $ 9.55 | USD |
Period:
Draw Mode:
Pharvaris NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 324.36M | 33.79M | 26.93M | $ - | $ - | -1.60 | -5.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
Pharvaris NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHVS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.01 | 9.79 | 8.7195 | 9.42 | 26,098 | 0.59 | 6.55% |
| 1 Month | 12.00 | 12.00 | 8.04 | 9.34 | 63,457 | -2.40 | -20.0% |
| 3 Months | 3.00 | 13.80 | 1.77 | 10.65 | 2,040,066 | 6.60 | 220.0% |
| 6 Months | 18.61 | 22.30 | 1.77 | 10.55 | 925,529 | -9.01 | -48.41% |
| 1 Year | 17.55 | 27.50 | 1.77 | 10.70 | 472,629 | -7.95 | -45.3% |
| 3 Years | 25.00 | 42.86 | 1.77 | 12.01 | 256,842 | -15.40 | -61.6% |
| 5 Years | 25.00 | 42.86 | 1.77 | 12.01 | 256,842 | -15.40 | -61.6% |
Pharvaris NV Description
| Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. |